article · Journal of sickle cell disease.
Abstract Objectives To determine the spectrum of ocular complications of sickle cell disease (SCD) and age of onset of proliferative sickle cell retinopathy (PSR) in children attending the paediatric clinic at a tertiary hospital in southern Ghana. Methods A cross-sectional study of all children with SCD in steady state, ages two to sixteen years. Demographic and clinical data were recorded using predesigned forms. The ocular manifestations of SCD were classified as either proliferative or non-proliferative based on the presence or absence of neovascularization, respectively. Results Included in this study were 294 children, (53.4% males), mean age 9.2±3.7 years and majority had HbSS-199 (67.9%) and HbSC- 74(25.3%) genotypes. Comma-shaped conjunctiva vessels were the commonest anterior segment manifestation occurring in 85% of children. Non-proliferative posterior segment signs included: venous tortuosity 69 (23.5%), salmon-patch hemorrhages 4 (1.4%), iridescent spots 38 (12.9%) and black sunburst 24 (8.2%). Prevalence of PSR of any stage among children with HbSS was 2.5% (5/199) and 8.1% (6/74) among those with HbSC (p = 0.0366). The earliest age PSR was detected in this cohort was eight years and for PSR stage three, 13 years. No child was blind from eye complications of SCD or any other cause. Conclusion: Comma-shaped conjunctiva vessels were the commonest anterior segment manifestation of SCD, and retinal venous tortuosity was the most common posterior segment manifestation. Proliferative retinopathy was more common in HbSC genotype.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1093/jscdis/yoag009
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.